Skip to main content
SpringerLink
Log in

Ranibizumab: A Review of its Use in Myopic Choroidal Neovascularization

  • Adis Drug Evaluation
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Ranibizumab (Lucentis®) is the first inhibitor of vascular endothelial growth factor (VEGF)-A licensed for the treatment of visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (i.e. myopic CNV). The drug inhibits biologically active isoforms of VEGF-A and is administered via intravitreal injection, with the number of treatments required depending on disease activity. The clinical benefit of such a ranibizumab regimen in adults with myopic CNV was demonstrated in a randomized, double-masked, active comparator-controlled, phase III trial known as RADIANCE. In this trial, intravitreal ranibizumab was superior to the standard licensed therapy available to these patients thus far, namely intravenous verteporfin plus photodynamic therapy (verteporfin PDT), in improving visual acuity from month 1 through month 3 of treatment, with improvements in some aspects of vision-related function also evident with ranibizumab versus verteporfin PDT at 3 months. Improvements in vision were sustained for up to 12 months in ranibizumab recipients and were mirrored by improvements in anatomic outcomes. Few ranibizumab injections were required over the trial, with more than 60 % of patients not needing to receive the drug from month 6 to 11. Ranibizumab was generally well tolerated in RADIANCE, with few patients experiencing serious ocular or non-ocular adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Silva R. Myopic maculopathy: a review. Ophthalmologica. 2012;228(4):197–213.

    Article  PubMed  Google Scholar 

  2. Wong TY, Ferreira A, Hughes R, et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2013;157(1):9–25.

    Article  PubMed  Google Scholar 

  3. Neelam K, Cheung CM, Ohno-Matsui K, et al. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res. 2012;31(5):495–525.

    Article  CAS  PubMed  Google Scholar 

  4. Green WR, Wilson DJ. Choroidal neovascularization. Ophthalmology. 1986;93(9):1169–76.

    Article  CAS  PubMed  Google Scholar 

  5. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141(3):456–62.

    Article  CAS  PubMed  Google Scholar 

  6. Pharm Asia News. Novartis’ Lucentis approved in Japan for choroidal neovascularization and macular edema. 2013. http://www.pharmamedtechbi.com/Publications/Pharmasia-News/2013/8/27/Novartis-Lucentis-Approved-In-Japan-For-Choroidal-Neovascularization-And-Macular-Edema. Accessed 3 Jun 2014.

  7. Novartis Europharm Limited. Lucentis 10 mg/mL solution for injection: EU summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf. Accessed 3 Jun 2014.

  8. Novartis International AG. Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization [media release]. 2013. http://www.novartis.com/newsroom/media-releases/en/2013/1714478.shtml.

  9. Genentech Inc. Lucentis (ranibizumab injection) intravitreal injection: US prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125156s094lbl.pdf. Accessed 3 Jun 2014.

  10. Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2007;85(4):425–30.

    Article  CAS  PubMed  Google Scholar 

  11. Carneiro A, Falcao M, Pirraco A, et al. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res. 2009;88(3):522–7.

    Article  CAS  PubMed  Google Scholar 

  12. Costa R, Carneiro A, Rocha A, et al. Bevacizumab and ranibizumab on microvascular endothelial cells: a comparative study. J Cell Biochem. 2009;108(6):1410–7.

    Article  CAS  PubMed  Google Scholar 

  13. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–85.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Yu L, Liang XH, Ferrara N. Comparing protein VEGF inhibitors: in vitro biological studies. Biochem Biophys Res Commun. 2011;408(2):276–81.

    Article  CAS  PubMed  Google Scholar 

  15. Spitzer MS, Yoeruek E, Sierra A, et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol. 2007;245(12):1837–42.

    Article  CAS  PubMed  Google Scholar 

  16. Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008;49(10):4523–7.

    Article  PubMed  Google Scholar 

  17. Silva RM, Ruiz-Moreno JM, Rosa P, et al. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina. 2010;30(3):407–12.

    Article  PubMed  Google Scholar 

  18. Lalloum F, Souied EH, Bastuji-Garin S, et al. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina. 2010;30(3):399–406.

    Article  PubMed  Google Scholar 

  19. Troutbeck R, Bunting R, van Heerdon A, et al. Ranibizumab therapy for choroidal neovascularization secondary to non-age-related macular degeneration causes. Clin Exp Ophthalmol. 2012;40(1):67–72.

    Article  Google Scholar 

  20. Ellabban AA, Tsujikawa A, Ogino K, et al. Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization. Clin Ophthalmol. 2012;6(1):837–44.

    CAS  PubMed Central  PubMed  Google Scholar 

  21. Mones JM, Amselem L, Serrano A, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye. 2009;23(6):1275–80.

    Article  CAS  PubMed  Google Scholar 

  22. Konstantinidis L, Mantel I, Pournaras J-AC, et al. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009;247(3):311–8.

    Article  CAS  PubMed  Google Scholar 

  23. Vadala M, Pece A, Cipolla S, et al. Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study. Br J Ophthalmol. 2011;95(5):657–61.

    Article  PubMed  Google Scholar 

  24. Tufail A, Patel PJ, Sivaprasad S, et al. Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study [Erratum appears in Eye. 2013;27(6):786]. Eye. 2013;27(6):709–15.

  25. Tufail A, Narendran N, Patel PJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013;120(9):1944–5.

    Article  PubMed  Google Scholar 

  26. Krohne TU, Liu Z, Holz FG, et al. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;154(4):682–6.

  27. Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2013;121(3):682–92 (plus supplementary appendix).

  28. Tan N, Wong T, Ishibashi T, et al. Impact of ranibizumab on patient-reported visual function in choroidal neovascularization secondary to pathologic myopia: 12 month results from RADIANCE [abstract]. In: 13th Euretina congress; 26–29 Sep 2013; Hamburg.

  29. Sharma YR, Tripathy K, Venkatesh P, et al. Aflibercept—how does it compare with other anti-VEGF drugs? Austin J Clin Opthalmol. 2014;1(3):8.

  30. Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121(1):150–61.

    Article  PubMed  Google Scholar 

  31. Novartis Pharmaceuticals. Observe the effectiveness and safety of ranibizumab in real life setting (LUMINOUS) [ClinicalTrials.gov identifier NCT01318941]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01318941?term=NCT01318941&rank=1. Accessed 22 May 2014.

  32. Iacono P, Parodi MB, Papayannis A, et al. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina. 2012;32(8):1539–46.

    Article  CAS  PubMed  Google Scholar 

  33. Gharbiya M, Giustolisi R, Allievi F, et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab—a randomized controlled trial. Am J Ophthalmol. 2010;149(3):458–64.

  34. National Institute for Health and Care Excellence. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia: NICE technology appraisal guidance 298. 2013. http://www.nice.org.uk/nicemedia/live/14305/65827/65827.pdf. Accessed 3 Jun 2014.

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit. Emma Deeks is a salaried employee of Adis/Springer.

Author information

Authors and Affiliations

  1. Adis, Level 1, The Warehouse Way, Northcote 0627; Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand

    Emma D. Deeks

Authors
  1. Emma D. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emma D. Deeks.

Additional information

The manuscript was reviewed by: P. Iacono, Fondazione G.B. Bietti-IRCCS, Rome, Italy; J. Monés, Institut de la Màcula i de la Retina and Barcelona Macula Foundation, Barcelona, Spain; J. M. Ruiz-Moreno, Department of Ophthalmology, Castilla La Mancha University, Spain; M. Stewart, Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deeks, E.D. Ranibizumab: A Review of its Use in Myopic Choroidal Neovascularization. BioDrugs 28, 403–410 (2014). https://doi.org/10.1007/s40259-014-0102-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-014-0102-5

Keywords

Search

Navigation